menu
    • menu

    Company profile for Orion Corporation

    Fermion-PSE
    News
    Orion’s partner Bayer in China for 3rd indication of darolutamide

    08 Jan 2025

    // PRESS RELEASE

    Orion and Marinus terminate agreement for ganaxolone in Europe

    02 Jan 2025

    // PRESS RELEASE

    Orion and Marinus terminate agreement for ganaxolone in Europe

    30 Dec 2024

    // #N/A

    DATA COMPILATION
    #PharmaFlow

    Fermion

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    pipeline-prospector-blog/pipeline-prospector-2024-highlights-rise-in-new-breed-of-biotechs-with-maiden-approvals-glp-1-meds-show-promise-beyond-obesity

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, etc.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orion CorporationFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, ...
    Telephone
    Telephone
    +358 10 4261
    Client Email
    Email
    fermionSales@fermion.fi
    Client Website
    Website
    https://www.orion.fi/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orion-corporation/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Orion’s partner Bayer in China for 3rd indication of darolutamide
    Orion’s partner Bayer in China for 3rd indication of darolutamide

    08 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2025/orions-collaboration-partner-bayer-submits-application-in-china-for-third-indication-of-darolutamide/

    PRESS RELEASE
    08 Jan 2025
    Share Share
    Orion and Marinus terminate agreement for ganaxolone in Europe
    Orion and Marinus terminate agreement for ganaxolone in Europe

    02 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

    PRESS RELEASE
    02 Jan 2025
    Share Share
    Orion and Marinus terminate agreement for ganaxolone in Europe
    Orion and Marinus terminate agreement for ganaxolone in Europe

    30 Dec 2024

    // #N/A

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

    #N/A
    30 Dec 2024
    Share Share
    Abilita and Orion Announce Research Collab to Next-Gen Antibody
    Abilita and Orion Announce Research Collab to Next-Gen Antibody

    19 Dec 2024

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-abilita-therapeutics-announce-research-collaboration-and-option-to-license-agreement-to-develop-innovative-antibody-therapeutics/

    PRESS RELEASE
    19 Dec 2024
    Share Share
    Orion Group Appoints Mikko as General Counsel Starting June 2025
    Orion Group Appoints Mikko as General Counsel Starting June 2025

    19 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/12/19/3000233/0/en/CORRECTION-Change-in-Orion-Group-Executive-Management-Board-as-of-1-June-2025-Mikko-Kemppainen-appointed-General-Counsel.html

    GLOBENEWSWIRE
    19 Dec 2024
    Share Share
    Change in Orion Group Executive Management Board
    Change in Orion Group Executive Management Board

    19 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/12/19/3000092/0/en/Change-in-Orion-Group-Executive-Management-Board-as-of-1-June-2025-Mikko-Kemppainen-appointed-General-Counsel.html

    GLOBENEWSWIRE
    19 Dec 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Orion, Abilita Collaborate on Antibody Therapeutics With Licensing Options

    Details:

    The collaboration combines Abilita's strength in discovering breakthrough antibody therapeutics for challenging membrane protein targets with Orion's proven expertise in oncology, pain.


    Lead Product(s): Antibody

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Large molecule

    Recipient: Abilita Therapeutics

    Deal Size: $785.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration December 18, 2024

    Fermion Orion Company Banner

    01

    Orion Corporation

    Finland
    arrow
    Pharmatech Expo 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Antibody

    Therapeutic Area : Oncology

    Highest Development Status : Discovery

    Recipient : Abilita Therapeutics

    Deal Size : $785.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Orion, Abilita Collaborate on Antibody Therapeutics With Licensing Options

    Details : The collaboration combines Abilita's strength in discovering breakthrough antibody therapeutics for challenging membrane protein targets with Orion's proven expertise in oncology, pain.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    December 18, 2024

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Orion and Alligator Bioscience Amend their Agreement Concerning Two Bispecific Antibodies

    Details:

    Orion will continue to developtwo bispecific antibodies, which are currently in late-stage pre-clinical development, successfully developed using Alligator’s RUBY bispecific format.


    Lead Product(s): Bispecific Antibody

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Large molecule

    Recipient: Alligator Bioscience

    Deal Size: $3.6 million Upfront Cash: Undisclosed

    Deal Type: Collaboration November 19, 2024

    Fermion Orion Company Banner

    02

    Orion Corporation

    Finland
    arrow
    Pharmatech Expo 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bispecific Antibody

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Alligator Bioscience

    Deal Size : $3.6 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Orion and Alligator Bioscience Amend their Agreement Concerning Two Bispecific Antibodies

    Details : Orion will continue to developtwo bispecific antibodies, which are currently in late-stage pre-clinical development, successfully developed using Alligator’s RUBY bispecific format.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    November 19, 2024

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges

    Details:

    ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.


    Lead Product(s): ODM-111

    Therapeutic Area: Neurology Brand Name: ODM-111

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 24, 2024

    Fermion Orion Company Banner

    03

    Orion Corporation

    Finland
    arrow
    Pharmatech Expo 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ODM-111

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges

    Details : ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.

    Brand Name : ODM-111

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 24, 2024

    Fermion Orion Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bayer Submits Third EU Indication Application for Darolutamide via Orion Collaboration

    Details:

    Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.


    Lead Product(s): Darolutamide,Androgen Deprivation Therapy

    Therapeutic Area: Oncology Brand Name: Nubeqa

    Study Phase: Phase IIIProduct Type: Small molecule

    Recipient: Bayer AG

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 14, 2024

    Fermion Orion Company Banner

    04

    Orion Corporation

    Finland
    arrow
    Pharmatech Expo 2025
    Not Confirmed
      <